Doris Benbrook to Animals
This is a "connection" page, showing publications Doris Benbrook has written about Animals.
Connection Strength
0.873
-
Targeting HSP70-E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer. J Med Virol. 2024 Nov; 96(11):e70088.
Score: 0.092
-
Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets. Cells. 2021 11 03; 10(11).
Score: 0.075
-
Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int J Cancer. 2020 08 15; 147(4):1086-1097.
Score: 0.066
-
Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Invest New Drugs. 2018 08; 36(4):561-570.
Score: 0.057
-
History of retinoic acid receptors. Subcell Biochem. 2014; 70:1-20.
Score: 0.043
-
Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. Cancer Prev Res (Phila). 2013 Sep; 6(9):908-16.
Score: 0.042
-
The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis. Curr Cancer Drug Targets. 2011 Jun; 11(5):586-99.
Score: 0.036
-
Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther. 2009 May; 8(5):1227-38.
Score: 0.031
-
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs. 2009 Aug; 27(4):304-18.
Score: 0.030
-
Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs. 2005 Oct; 23(5):417-28.
Score: 0.024
-
Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing. AAPS J. 2023 Dec 12; 26(1):5.
Score: 0.022
-
Niclosamide causes lysosome-dependent cell death in endometrial cancer cells and tumors. Biomed Pharmacother. 2023 May; 161:114422.
Score: 0.020
-
Refining retinoids with heteroatoms. Mini Rev Med Chem. 2002 Jun; 2(3):277-83.
Score: 0.019
-
An ELISA method for detection of human antibodies to an immunotoxin. J Pharmacol Toxicol Methods. 2002 May-Jun; 47(3):169-75.
Score: 0.019
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1. Autophagy. 2021 Jan; 17(1):1-382.
Score: 0.018
-
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2021 01; 160(1):302-311.
Score: 0.017
-
Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile. J Pharm Sci. 2020 06; 109(6):2000-2008.
Score: 0.017
-
Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51.
Score: 0.017
-
Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J Med Chem. 1999 Oct 21; 42(21):4434-45.
Score: 0.016
-
Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research. Geroscience. 2019 04; 41(2):209-227.
Score: 0.016
-
Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships. J Med Chem. 1998 Sep 10; 41(19):3753-7.
Score: 0.015
-
Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. J Pharm Sci. 2018 12; 107(12):3179-3186.
Score: 0.015
-
Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. Eur J Pharm Biopharm. 2018 Sep; 130:272-280.
Score: 0.015
-
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. PLoS One. 2018; 13(4):e0194046.
Score: 0.015
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
Score: 0.015
-
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. J Med Chem. 1997 Oct 24; 40(22):3567-83.
Score: 0.014
-
Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia. J Pharm Sci. 2018 02; 107(2):638-646.
Score: 0.014
-
Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice. Immunology. 2017 09; 152(1):36-51.
Score: 0.014
-
Label-Free Real-Time Microarray Imaging of Cancer Protein-Protein Interactions and Their Inhibition by Small Molecules. Anal Chem. 2016 Mar 15; 88(6):3130-5.
Score: 0.013
-
Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. Drug Chem Toxicol. 2013 Jul; 36(3):284-95.
Score: 0.010
-
Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. Mutat Res. 2012 Jul 04; 746(1):78-88.
Score: 0.010
-
Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene. 2012 May 31; 31(22):2725-37.
Score: 0.009
-
Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008 Nov; 22(21):3371-81.
Score: 0.008
-
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008 Jul 01; 68(13):5335-44.
Score: 0.007
-
High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother Pharmacol. 2006 Nov; 58(5):561-9.
Score: 0.006
-
Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. Proc Natl Acad Sci U S A. 2003 Jun 10; 100(12):7135-40.
Score: 0.005
-
Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res. 2002 Nov; 8(11):3520-6.
Score: 0.005
-
Complexity, retinoid-responsive gene networks, and bladder carcinogenesis. Adv Exp Med Biol. 1999; 462:449-67.
Score: 0.004
-
A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol. 1994 Oct; 14(10):7025-35.
Score: 0.003